Pediatric Clinical Trials

Pediatric Neuroblastoma

If you would like to inquire about all open trials, please contact 919.684.3401.

2 trials identified.

An Open Label, Expanded Access Protocol Using (131)I-Metaiodobenzylguanidine (I-MIBG) Therapy in Patients with Refractory Neuroblastoma
Phase: Other
Sponsor: OTHER
Principal Investigator: Michael Armstrong
Contact: Dr. Michael Armstrong
Phone: 919.684.3401
Purpose: Primary Objectives: - Provide palliative therapy with 131I-MIBG for patients with advanced neuroblastoma, pheochromocytoma, or paraganglioma. - Gain more information about acute and late toxicity of 131I-MIBG therapy for patients with refractory neuroblastoma, pheochromocytoma, or paraganglioma.
Reference Number: 00012332
View this trial at

ANBL1221 A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 764038, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma
Phase: Phase II
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Dr. Susan Kreissman
Phone: 919.684.3401
Purpose: This randomized phase II trial studies how well irinotecan hydrochloride and temozolomide with temsirolimus or dinutuximab work in treating younger patients with neuroblastoma that has returned or does not respond to treatment. Drugs used in chemotherapy, such as irinotecan hydrochloride and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as dinutuximab, may find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether giving irinotecan hydrochloride and temozolomide together with temsirolimus or dinutuximab is more effective in treating neuroblastoma.
Reference Number: 00044246
View this trial at